°²öÎÓéÀÖ¹ÙÍø

°²öÎÓéÀÖ¹ÙÍøÑÛ¿Æ
Ä¿½ñλÖ㺠Ê×Ò³ > ¾ÍÕïÖ¸ÄÏ > ³£¼ûÑÛ²¡ÐÂÎÅ > ÕýÎÄ

°²öÎÓéÀÖ¹ÙÍøÑÛ¿ÆÐÐÒµ×ÊѶ£º2018ÄêÑÛÍâÉËÁìÓòÈÈÃÅÓëÕ¹Íû

×÷ÕߣºÎ´Öª 2019-01-26 13:15:23
×ÖÌå´óС£º
¡¾µ¼¶Á¡¿°²öÎÓéÀÖ¹ÙÍøÑÛ¿ÆÐÐÒµ×ÊѶ£º2018ÄêÑÛÍâÉËÁìÓòÈÈÃÅÓëÕ¹Íû

¡¡¡¡°²öÎÓéÀÖ¹ÙÍøÑÛ¿ÆÐÐÒµ×ÊѶ£º2018ÄêÑÛÍâÉËÁìÓòÔÚ¶àÄêÀ´ÎȲ½Éú³¤µÄ»ù´¡ÉÏ £¬Ò»Ö±ÍØÕ¹  £¬ÁÙ´²ºÍ»ù´¡Ñо¿¾ùÈ¡µÃÁËÖî¶àÏ£Íû £¬ÕûÌåѧÊõˮƽһÁ¬ÌáÉý £¬´ó×Ú¸ßˮƽѧÊõÂÛÎÄÓë׍ָ½ÒÏþÓÚ¾ÙÊÀ×ÅÃû³öÊéÎïºÍÆÚ¿¯¡£ÏÖ¶Ô2018ÄêÑÛÍâÉËÁìÓòÑо¿ÈÈÃÅ×öһϵͳ»ØÊ׺Í×ܽá¡£


¡¡¡¡¹úÈËÖ÷±àµÄ¾ÙÊÀÑÛÍâÉËÊé¼®

¡¡¡¡Ëæ×Å»¯¹¤ÆóÒµ¡¢Í¨Ë×ÀèÃñ¶ÔÑÛÍâÉ˵ÄÖØÊÓ¡¢·À»¤ÒâʶµÄÌá* £¬ÎÒ¹úÑÛÍâÉËÖзǻúеÐÔÑÛÍâÉËÏà¶Ô½ÏÉÙ £¬»úеÐÔÑÛÍâÉËÕ¼´ó´ó¶¼¡£»úеÐÔÑÛÍâÉËÏÖÒѳÉΪÎÒ¹ú³£¼ûµÄÑۿƼ±Ö¢ £¬ÑÏÖØÓ°Ï컼ÕßÊÓ¹¦Ð§¼°ÉúÑÄÖÊÁ¿¡£ÎÒ¹ú»úеÐÔÑÛÍâÉË»¼ÕßÊýÄ¿ÖØ´ó £¬µ«¾ÙÊÀÉϹØÓÚ»úеÐÔÑÛÍâÉË·½ÃæµÄÊé¼® £¬ÏÕЩûÓÐÖйúÈ˵£µ±Ö÷±à £¬²¿·ÖѧÕßÒ²Ö´ÙǼÓÈëһЩÍâÑóÑÛÍâÉËÊé¼®µÄ±àд £¬Ã»ÓÐÕæÕýµÄ»°ÓïȨ¡£×÷ΪÎÒ¹úÑÛÍâÉË ÁìÓòµÄÁìÎäÊ¿Îï £¬Ìì½òÒ½¿Æ´óѧ×ÜÒ½ÔºÑÕ»ª½ÌÊÚÓ¦Springer³öÊéÉÌÔ¼Çë £¬Ö÷±àÁËMechanical Ocular Trauma: Current Consensus and ControversyÒ»Êé¡£´ËÊéÓëÆäËûÑÛÍâÉË׍ָ²î±ð £¬ÕõÍÑÁËÒÔÍùÊé¼®Æ¬ÃæÇ¿µ÷´ó¶øÈ«µÄ¹ÌÓÐÍ·ÄÔ £¬¸ü¾ßÓÐÕë¶ÔÐÔ £¬Ç¿µ÷»úеÐÔÑÛÍâÉËÁìÓòµÄÄѵ㼰ÕùÒéÎÊÌâ £¬Í¬Ê±Ò²Éæ¼°ÍâÉËÎÞ¹â¸ÐÑÛ¡¢Ñ¬È¾ÐÔÑÛÄÚÑס¢ÑÛÄÚÒìÎïµÈ½üЩÄêÒ½ÖÎÉÏÓÐÐÂÍ»ÆÆµÄÄÚÈÝ¡£´ËÊéµÄ³öÊé˵Ã÷¾ÙÊÀÑۿƽç¶ÔÎÒ¹úÑÛÍâÉËÔ¤·À¡¢Ò½ÖÎÒªÁì¡¢¾ÈÖÎˮƽÒÔ¼°ÐÂÊÖÒÕÉϵĸ߶ÈÈÏ¿É £¬µÓÚ¨ÎÒ¹úÑÛÍâÉËÁìÓò¸ü¸ßµÄ¾ÙÊÀְλ¡£


¡¡¡¡ÖØ´óС¶ùÑ۵ײ¡ÐÂÕïÁÆÄ£Ê½µÄ̽Ë÷

¡¡¡¡ÔÚÊ×¶¼Ò½¿Æ´óѧÁ¥Êô±±¾©Í¬ÈÊҽԺ¬º£½ÌÊÚÏòµ¼Ï £¬Í¬ÈÊС¶ùÑ۵ײ¡ÍŶÓÒÀÍжùͯȫÉíÂé×íÏÂRetcam¹ãÓòÑÛµ×ÕÕÏà¡¢ÑÛµ×Ó«¹âѪ¹ÜÔìÓ°ÒÔ¼°UBM¼ì²éÊÖÒÕ £¬¿ªÕ¹½Þ×´Ì寽չ²¿¼°½ÇĤԵÈë·΢´´²£Á§ÌåÊÖÊõÒ½ÖÎÓÀ´æÔ­Ê¼²£Á§ÌåÔöÉúÖ¢(PFV)¡¢Î¢´´²£Á§ÌåÊÖÊõÍŽáÑÛÄÚ×¢Ò©Ò½ÖζùͯÑÛ¹­»×³æ²¡¡¢27G΢´´¹®Ä¤Íâ·ÅҺ͎ΌVEGFÒ©ÎïÒ½ÖÎCoats²¡µÈÒ½ÖÎ £¬²¢¶ÔÊõºóÇü¹â״̬¾ÙÐзÃÊÓ £¬Öƶ©ÊÓ¾õ ѵÁ·¼Æ»® £¬ÔÚº£ÄÚÍâÈ¡µÃÁËÒ»¶¨µÄÁÙ´²¿ÆÑÐЧ¹û¡£

¡¡¡¡ÍŶÓÒ»Ïî105ÈË(118ÑÛ)µÄ¾­½Þ×´Ì寽չ²¿Èë·΢´´¾§×´Ìå²£Á§ÌåÇгýÊõÒ½ÖÎPFVµÄ´óÑù±¾»ØÊ×ÐÔÑо¿·¢Ã÷ £¬84ÑÛ(71.2%)µÄÊõºóÊÓÁ¦»ñµÃ Ìá*¡£ÆäÖÐ £¬ÄêËêСÓÚ2ËêµÄ»¼¶ùÖÐǰ²¿PFVºÍÒ»ÆÚÈ˹¤¾§×´ÌåÖ²ÈëÓëÆäÊõºóÊÓ¹¦Ð§Ë®Æ½µÄÌá*Ç×½üÏà¹Ø¡£Ò»Ïî41ÈË(41ÑÛ)µÄ¶ùͯÑÛ¹­»×³æ²¡µÄUBMÓ°ÏñÑ§ÌØµãµÄ»ØÊ×ÐÔÑо¿·¢Ã÷ £¬²£Á§Ìå»ùµ×²¿¼°½Þ×´ÌåÈâÑ¿Ö×ÐÔÑ×Ö¢·´Ó¦¶à¼ûÓÚò¨Ï¼°±Ç²à £¬²¢½Ï¼ä½Ó¼ìÑÛ¾µ¼ì²éÃô¸ÐÐÔ¸ü¸ß £¬¶¨Î»Ô½·¢×¼È· £¬ÌáÐÑÊõǰUBM¼ì²éÔÚ²£Á§ÌåÊÖÊõÈë·µÄÑ¡Ôñ¼°²¢·¢Ö¢µÄÔ¤·ÀÉϾ߱¸Ò»¶¨ÓÅÊÆ¡£Ò»Ïî17ÈË(17ÑÛ)µÄÈýÆÚCoats²¡Ðò¹áÒ½Ò½ÖÎЧµÄǰհÐÔÑо¿·¢Ã÷ £¬ÔçÆÚ²£Á§ÌåÇ»¿¹VEGFÒ©ÎïʹÓà £¬²¢ÒÀ¾ÝÊÓÍøÄ¤ÏÂÒºÁ¿µÄת±ä £¬ÍŽáÊÓÍøÄ¤¼¤¹â¹âÄý¼°Àä¶³Ò½ÖÎ £¬¾­ÓÉÆ½¾ù2.82¡À0.95¸öÁƳÌ £¬7ÑÛ(41.18%)ÊÓ¹¦Ð§»ñµÃÌá* £¬ÌáÐѸÃÒ½ÖÎÕ½ÂÔÄܹ» ¿ØÖÆ3ÆÚCoats²¡µÄ²¡ÇéÏ£Íû¡£


¡¡¡¡Ô¤·À¼°Ò½ÖÎÑÏÖØÑÛÇòήËõµÄÐÂÒªÁì

¡¡¡¡´ÓÈ«Çò¹æÄ£À´¿´ £¬ÑÛÍâÉËÊǵ¥ÑÛÊÓÁ¦²Ð¼²µÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ £¬ÔÚÎÒ¹úÑÛÍâÉËÔòÊǵ¥ÑÛäµÄÊ×λÖÂϹÑÛ²¡¡£ÆäÖÐÓв¿·Ö»¼ÕßÒòÍâÉ˵¼ÖÂÑÏÖØµÄÑÛÇòήËõ £¬ÏÖÔÚͨÀýµÄÒ½ÖÎÒªÁìÍùÍùÄÑÒÔ±£×¡ÑÛÇò £¬¾­³£ÐèÒªÕª³ýÑÛÇòÖ²ÈëÒåÑŲ̂ £¬¶øÕâЩ»¼Õß¶àΪ¶ùͯºÍÇà׳Äê £¬ÔÚÊÓÁ¦ËðʧµÄͬʱ¶Ô»¼ÕßµÄÉç»áÒâÀíÒ²±¬·¢ÖØ´ó¹¥»÷¡£ËÕÖÝ´óѧÁ¥ÊôÀíÏëÑÛ¿ÆÒ½ÔºÑîÑ«½ÌÊÚ´ÓÊÂÑÏÖØÑÛÍâÉË»¼ÕßÄÚ¿ú¾µÏ²£ÇÐÒ½ÖÎ15ÄêÀ´ £¬ÊµÑéµÄÄÚ¿ú¾µÏ²£ÇÐ ÊÖÊõÉÏǧ  £¬±»ÍâÑóÙÉÐгÆÎª¡°King of Ocular Endoscopy(ÑÛÄÚ¿ú¾µÖ®Íõ)¡± £¬½üÄêÀ´ÖÂÁ¦ÓÚÑÛÍâÉËËùÖÂÔçÆÚÑÛÇòήËõÔ¤·À¼°Ò½ÖεÄÒªÁìÑо¿ £¬½ÒÏþµÄ4ƪ¾Û»áÂÛÎı»SCIÊÕ¼(Ó°ÏìÒò×Ó1.676)²¢×ܽá³öÒÔÏÂ4ÖÖÒªÁ죺¢ÙÄÚ¿ú¾µÏ½Þ״Ĥ°þ³ýÊõ £¬´Ó¶øÔöÌí·¿Ë®ÉøÍ¸ºÍïÔÌ­½Þ×´ÌåÄÚÏòÇ£À­;¢Ú¶Ô̻¶µÄRPE¾ÙÐйâÄýÊõ £¬ïÔÌ­·¿Ë®µÄÁ÷³ö;¢ÛСÁºÍøÒ»Á¬¹âÄý £¬ïÔÌ­·¿Ë®Á÷³ö;¢Ü²£Á§ÌåÇгýÊõºóÒ»Á¬×¢ÓÍ £¬´Ó¶ø×èÖ¹ÂöÂçĤˮÖ×ÏûÍ˺óµÄÌî³äȱ·¦ºÍÑÛѹһÁ¬Ï½µ;ʵ¼ù֤ʵÒÔÉÏÒªÁì¿ÉÒÔÔ¤·À¼°Ò½Öδ󲿷ֵÄÔçÆÚÑÛÇòήËõ £¬Ê¹»¼Õß×èÖ¹Õª³ýÑÛÇòµÄÍ´¿à¡£¸ÃÊÖÒÕ±»ÆÀΪ2010~2014ÄêÖйúÑÛÍâÉËÊ®*Ï£ÍûÖ®Ò»¡£

¡¡¡¡¿ÉÊÇ £¬ÔÚÑÏÖØÑÛÇòήËõ»¼ÕßµÄÊÖÊõÒ½ÖÎÖÐ £¬ÈÔÈ»ÃæÁÙÑÛÄÚÈÝ»ýС¡¢ÊÖÊõ²Ù×÷¿Õ¼ä ¾ÖÏÞºÍÊÖÊõÖÐÊÓÍøÄ¤Ãæ»ý ´óÓÚήËõÑÛÄÚ²àÃæ»ýÎÞ·¨ÆÌƽ²¢ÄÑÒÔ¸´Î»µÈÕϰ­ £¬Ê¹ÑÏÖØÑÛÇòήËõ¾­³£³ÉΪÊÖÊõ½ûÇø¡£ÎªÁËÔÚ²£ÇÐÊÖÊõǰÔöÌíÑÛÄÚÈÝ»ý¡¢ÕùÈ¡ÊÖÊõ ʱ»ú £¬ÑîÑ«½ÌÊÚ2017Äê*´´Á˲£Á§ÌåÇ»×¢ÆøÍŽá𤵯¼ÁÌî³ä £¬´ýÑÛÄÚÈÝ»ý ºóÔÙ¾ÙÐв£ÇÐ £¬ÎªÑÏÖØÎ®ËõµÄÑÛÇòÌṩÁËÊÖÊõʱ»ú £¬ÍŽáǰÊö4ÖÖÒ½ÖÎÔçÆÚÑÛÇòήËõµÄÒªÁì £¬ÁÙ´²ÉÏ»ñµÃÁË½ÏºÃµÄÆðԴЧ¹û £¬ÎªÑÏÖØÑÛÇòήËõµÄÒ½Öοª·¢ÁËÐÂµÄ Í¾¾¶¡£


¡¡¡¡¶àµãµç×¢ÊÓÍøÄ¤ÇпªÊõµÄÉè¼ÆºÍÁÙ´²Ó¦ÓÃ

¡¡¡¡ÖØ´ó»òÄÑÖÎÐÔÊÓÍøÄ¤ÍÑÀë £¬³£¾ß±¸²¡ÇéÖØ´ó¡¢Ò½ÖÎÄѶȴóºÍ¸´·¢ÂʸߵÈÌØµã £¬ÊÇÁÙ´²Ò½ÉúºÍ»¼ÕßÅäºÏÃæÁÙµÄÌôÕ½¡£ÊÓÍøÄ¤ÔÙ´ÎÍÑÀëµÄÖ÷ÒªÔµ¹ÊÔ­ÓÉÊÇÑÏÖØPVR £¬ËɽâÐÔÊÓÍøÄ¤ÇпªÊõÊÇÁÙ´²Éϳ£ÓÃÇÒ µÄÊÖÊõ·½·¨¡£È»¶ø £¬Ëæ×ŸÃÊÖÊõµÄÆÕ±é¿ªÕ¹ £¬Ïà¹Ø²¢·¢Ö¢Öð½¥»ñµÃ¸ü¶àµÄÖØÊÓ£ººÃ±ÈÕý³£ÊÓÍøÄ¤±»ÆÈÇпª¡¢Êõºó´óÃæ»ýÊÓÍøÄ¤È±Ëð¡¢ÊõÖÐÒ׳öѪ¡¢ÊõºóµÍÑÛѹµÈ¡£Õë¶ÔÕâЩÀ§ÈÅÒѾõÄÎÊÌâ £¬ÖÐɽ´óѧÖÐɽÑÛ¿ÆÖÐÐÄÁÖÏþ·å½ÌÊÚ¶Ô´ËÊÖÊõ¾ÙÐиÄÁ¼ £¬Ìá³ö¶àµãµç×¢ÊÓÍøÄ¤ÇпªÊõ£º½ÓÄÉ¡°·äÎÑ×´Çпª¡±µÄÐÎʽ £¬Ê¹ÓõçÄýµ¶ÑØ×ÅÊÓÍøÄ¤ÖåËõ·½Î»×öµã×´ÇпÚ £¬ÉÈÐÎÂþÑܵÄÔ²µã×´ÇÐ¿Ú ÏÞÖÆÔÚÔöÖ³Ôî¹æÄ£ÄÚ;Ô²µã×´ÇпÚÔÚ¹èÓ͵ÄѹÁ¦Ïµ¯ÐÔÀ©ÕÅ £¬Åâ³¥ÒòÖåËõ¶øËðʧµÄÊÓÍøÄ¤Ãæ»ý £¬ÊµÏÖÉÙÁ¿ËðʧÊÓÍøÄ¤µÄÌõ¼þϵִïÊÓÍøÄ¤¸´Î»¡£¸ÃÍŶÓÒÑÍê³É̽Ë÷ÐÔÁÙ´²ÊÔÑé(ClinicalTrials.gov ID£ºNCT02201706) £¬Ö¤ÊµÁ˸ÃÊõʽҽÖÎÖØ´óÊÓÍøÄ¤ÍÑÀëµÄ¿ÉÐÐÐÔ¡¢ ÐÔÓëÇå¾²ÐÔ¡£Ñо¿Ð§¹ûÓÚ2016ÄêÃÀ¹úÑÛ¿ÆÄê»á×öÏÖ³¡»ã±¨ £¬²¢½ÒÏþÔÚJournal of OphthalmologyÔÓÖ¾¡£ÁÖÏþ·å½ÌÊÚÔÚ¾ÙÊÀÉÏÊ×ÏÈÌá³öµÄ¶àµãµç×¢ÊÓÍøÄ¤ÇпªÊõ £¬ÓɸÄÁ¼Éè¼ÆµÄÀíÄî¹âÁÙ´²ÊÔÑéµÄÍê³É £¬ÊÇ´ÓÁÙ´²·¢Ã÷ÎÊÌâ¡¢Ñо¿Ð§¹û½â¾öÁÙ´²ÎÊÌâµÄµä·¶Ê÷Ä£¡£´ËÏîÑо¿Ð§¹û½«ÎªÖØ´óÊÓÍøÄ¤ÍÑÀ뻼ÕßµÄÒ½ÖÎÌṩÇå¾²¡¢ µÄ´ýÑ¡ÊÖÊõ·½·¨¡£


¡¡¡¡¸ÄÁ¼Î¢´´¹®Ä¤ÄÚÊÖÊõÒ½ÖÎÍâÉËÐÔÎÞ¾§×´ÌåÑÛ

¡¡¡¡¸´µ©´óѧÁ¥ÊôÎ÷ÔÀÒ½ÔºÑÛ¿ÆÍõÖ¾Á¼½ÌÊÚÑо¿ÍŶÓͨ¹ý¸ÄÁ¼µÄ΢´´¹®Ä¤ÄÚÀο¿¿ÉÕÛµþʽÈ˹¤¾§×´Ìå £¬ Ò½ÖÎûÓо§×´ÌåÄÒ´ü»òºçĤ֧³ÖµÄÍâÉËÐÔÎÞ¾§×´ÌåÑÛ»¼Õß¡£¸ÃÊÖÊõ·½·¨½ÓÄÉ23G΢´´ÇпÚ £¬¿ÉÕÛµþµÄÈ˹¤¾§×´Ìå΢ÇпÚ £¬ÎÞÐ蹮Ĥ°êµÄÈ˹¤¾§×´ÌåÄÚÀο¿ £¬¾ßÓÐ΢´´¡¢Çå¾²¡¢¸ßЧµÄÊÖÊõÌØµã £¬Ê¹ÎÞ¾§×´Ì廼Õß»ñµÃÖª×ãµÄÊÓ¹¦Ð§¡£¸ÃÑо¿½ÒÏþÔÚJournal of Cataract & Refractive SurgeryÔÓÖ¾ÉÏ¡£

¡¡¡¡¿×Ô´ÐÔÊÓÍøÄ¤ÍÑÀëÒ½ÖÎÐÂÒªÁì

¡¡¡¡¹®Ä¤¿Û´øÊõ×÷ΪҽÖο×Ô´ÐÔÊÓÍøÄ¤ÍÑÀë(RRD)µÄÒªÁìÒÑÓÐÁè¼Ý60ÄêµÄÀúÊ·¡£½ü20ÄêÀ´ £¬²£Á§ÌåÇгýÊõÒѱ»ÆÕ±éÓ¦ÓÃÓÚRRDµÄÒ½ÖÎ £¬µ«¹®Ä¤¿Û´øÊõÈÔ¾ßÓÐÆäÓÅÊÆ¡£¹Å°å¹®Ä¤¿Û´øÊõ²Ù×÷ʱ £¬ÊõÕßͨ¹ý¼ä½ÓÑÛµ×¾µÊӲ컼ÕßÑÛµ× £¬ÊõÕß×ËÊÆÊܵ½Ò»¶¨ÏÞÖÆ £¬ÇÒÊÖÊõʱ¼ä½Ï³¤ £¬ÊõÕßÈÝÒׯ£ÀÍ¡£±ðµÄ¼ä½ÓÑÛµ×¾µÏÂËù¿´µ½Îªµ¹ÖõÄÑÛµ×ͼÏñ £¬¶ÔÊõÕßÌá³öÁ˸ü¸ßµÄÊÖÒÕÒªÇó £¬Í¬Ê±Ò²Ó°ÏìÊõÖжԼ²²¡µÄÈ«·½Î»ÆÀ¼Û¡£Ìì½òÒ½¿Æ´óѧ×ÜÒ½ÔºÑÛ¿ÆÑÕ»ª½ÌÊÚ¶Ô¹®Ä¤¿Û´øÊõµÄÊÖÊõÒªÁì¾ÙÐÐÁ˸ÄÁ¼ £¬¼´½«·Ç½Ó´¥¹ã½ÇÊÓ²ìϵͳ¡¢Î¢´´ÑÛÄÚÕÕÃ÷ϵͳÓ빮Ĥ¿Û´øÊõÏàÍŽá £¬ÊõÕß¿ÉÔÚÌñ¾²µÄ×ËÊÆÏ¾ÙÐÐÊÖÊõ £¬ÊõÕß²»Ò×±¬·¢Æ£ÀÍ¡£·Ç½Ó´¥¹ã½ÇÊÓ²ìϵͳ¿ÉÌṩһ¸öÕýλµÄÑÛµ×ͼÏñ £¬ÊÓ²ì¹æÄ£¸ü¹ã¡¢¸üÇåÎú £¬Äܹ»ÏÔ×ÅËõ¶ÌÊÖÊõʱ¼ä £¬ïÔÌ­Êõºó²¢·¢Ö¢¡£±ðµÄ £¬¸ÄÁ¼µÄÊÖÊõ·½·¨Ëõ¶ÌÁ˳õѧÕßµÄѧϰÇúÏß £¬¸üÈÝÒ×½øÒ»²½ÍƹãÓ¦Ó᣸ÃÑо¿½ÒÏþÔÚEuropean Journal of OphthalmologyÔÓÖ¾ÉÏ¡£


¡¡¡¡»ù´¡Ñо¿

¡¡¡¡¿ª·ÅÐÔÑÛÍâÉ˵ľ«×¼ÆÊÎö

¡¡¡¡¿ª·ÅÐÔÑÛÍâÉËÐèÒªÊÖÊõ·ìºÏÉË¿Ú £¬¿ÉÊǹŰåµÄ×ö·¨Ö»ÊÇÓÃÁÑ϶µÆÀ´ÆÀ¼ÛÉ˿ڶԺÏˮƽºÍÓúºÏÇéÐÎ £¬ÓнϴóµÄÖ÷¹ÛÐÔ £¬²¢ÇÒÎÞ·¨¿Í¹Û¼Í¼ £¬Ö»Äܶ¨ÐÔÆÀ¼Û¡£ÉÇÍ·´óѧ¡¤Ïã¸ÛÖÐÎÄ´óѧÍŽáÉÇÍ·¾ÙÊÀÑÛ¿ÆÖÐÐijºÆÓî½ÌÊÚÑо¿ÍŶÓÓÃǰ¶ÎOCTÀ´ÆÀ¼Û½ÇĤÉË¿Ú £¬°Ñ½ÇĤÉ˿ڷìºÏºóµÄÐÎ̬·ÖΪËÄÖÖÀàÐÍ £¬²¢ÇÒ¶¨Á¿ÕÉÁ¿É˿ڵĽÇĤºñ¶È¡¢ÄÚ¿Ú´íλ¾àÀë¡¢ÄÚ¿ÚÕÅ¿ª¾àÀë¡¢¹âÃܶȵȲÎÊý¡£Ð§¹û·¢Ã÷½ÇĤÍâÉË·ìºÏºóËæ·ÃÀú³ÌÖÐÉË¿ÚÐÎ̬¿ÉÒÔ±¬·¢×ª»» £¬É˿ڴ¦½ÇĤºñ¶ÈÖð½¥½µµÍ¡¢ÄÚ¿Ú´íλ¾àÀëÖð½¥ËõС £¬ÄÚ¿ÚÕÅ¿ª¾àÀëÖð½¥ËõС £¬¹âÃܶÈÖð½¥Ôö´ó £¬Ô¼ÄªÔÚÊõºó3~6¸öÔ¸÷Ïî²ÎÊýÇ÷ÓÚÎȹÌ¡£²¢ÇÒÊõºó6¸öÔµĹâÃܶÈÓëÊõºó1ÌìµÄÄÚ¿Ú´íλ¾àÀë³ÊÕýÏà¹Ø £¬Ò²¾ÍÊÇ˵ÊõºóÄÚ¿Ú´íλԽ´ó £¬ÓúºÏºóµÄñ£ºÛÔ½ÑÏÖØ¡£¸ÃÑо¿Ê״ζԿª·ÅÐÔÑÛÍâÉ˵ĽÇĤÉ˿ھÙÐо«×¼ÆÊÎö £¬²¢ÇÒÌá³öÁËΪÁËïÔÌ­Êõºóñ£ºÛ £¬Ó¦ÔÚ·ìºÏÖÐÖ»¹Ü×èÖ¹ÄÚ¿Ú´íλ £¬¶ÔÁÙ´²ÓÐÒ»¶¨Ö¸µ¼ÒâÒå¡£¸ÃÑо¿·ÖÁ½ÆªÂÛÎĽÒÏþÔÚScientific ReportsºÍCurrent Eye ResearchÉÏ¡£


¡¡¡¡ÕÒµ½ÑÛÄÚÑ×Ñ×Ö¢¿ØÖƺóÊÓÁ¦²îµÄÔµ¹ÊÔ­ÓÉ

¡¡¡¡ÑÛÄÚÑײ¿·Ö»¼ÕßÔÚÑ×Ö¢¿ØÖƺóÈÔÈ»ÊÓÁ¦²î £¬Ôµ¹ÊÔ­ÓÉÉÐδÃ÷È·¡£ÉÇÍ·´óѧ¡¤Ïã¸ÛÖÐÎÄ´óѧÍŽáÉÇÍ·¾ÙÊÀÑÛ¿ÆÖÐÐijºÆÓî½ÌÊÚÑо¿ÍŶÓʹÓÃÆµÓòOCT¶ÔÑÛÄÚÑ×»¼ÕߵĻưßÇøÏÔ΢½á¹¹¾ÙÐÐÑо¿¡£Ð§¹û·¢Ã÷ÑÛÄÚÑ×ÔÚÑ×Ö¢¿ØÖƺó¿ÉÒÔ·ºÆðËÄÖÖÏÔ΢½á¹¹¸Ä±ä£º¹â¸ÐÊÜÆ÷ÄÚ½ÚÍÖÔ²Ìå´øÖÐÖ¹¡¢ÊÓÍøÄ¤ÄÚ²ãήËõ¡¢»Æ°ßǰĤ¡¢»Æ°ßÄÒÑùË®Öס£½øÒ»²½µÄÆÊÎö·¢Ã÷±¬·¢¹â¸ÐÊÜÆ÷ÄÚ½ÚÍÖÔ²Ìå´øÖÐÖ¹»òÕßÊÓÍøÄ¤ÄÚ²ãήËõµÄ»¼ÕßÊÓÁ¦±È²»±¬·¢µÄ»¼Õß²î £¬¶àÔªLogistic»Ø¹éÆÊÎö·¢Ã÷ÊÓÍøÄ¤ÄÚ²ãήËõÊÇ Ò»¸ö×ÔÁ¦Ó°ÏìÊÓÁ¦µÄÒòËØ¡£ÊÓÍøÄ¤ÄÚ²ãήËõ¼ûÓÚÊÓÍøÄ¤È±ÑªÐÔ¼²²¡ £¬ÍƲâÑÛÄÚÑ×·¢²¡Àú³ÌÖÐÑ×֢ϸ°ûÛÕ±ÕÊÓÍøÄ¤Ñª¹Ü £¬µ¼ÖÂËù¹©Ó¦µÄÊÓÍøÄ¤ÄÚÎå²ãȱѪȱÑõ £¬ ºóήËõ¡£¸ÃÑо¿Ê×´ÎÌá³öÁËȱѪÔÚÑÛÄÚÑײ¡ÀíÐÄÀíÀú³ÌÖеÄ×÷Ó᣸ÃÑо¿½ÒÏþÔÚEyeÔÓÖ¾ÉÏ¡£


¡¡¡¡ÎÞ´´ÐÔÊÓÍøÄ¤ÑªÑõ±¥ºÍ¶È¼ì²âÔÚÖÖÖÖÑÛÍâÉËÖеÄÓ¦ÓÃ

¡¡¡¡ÑÛÍâÉËÓÈÆäÊDZպÏÐÔÑÛ´ìÉËÍùÍùÒýÆðÊÓÍøÄ¤ÑªÒºÁ÷±äѧµÄ¸Ä±ä £¬´Ó¶øµ¼ÖÂÊÓÍøÄ¤µÄ²»ÄæË𺦠£¬µ«ÍâÉ˺óµÄÊÓÍøÄ¤ÑªÑõ´úл¸Ä±äÇéÐÎÈÔ²»Ã÷Îú¡£ÖÐɽ´óѧÖÐɽÑÛ¿ÆÖÐÐÄÁÖÏþ·å½ÌÊÚÑо¿ÍÅ¶Ó ½ÓÄÉÎÞ´´ÐÔµÄÊÓÍøÄ¤ÑªÑõ±¥ºÍ¶È¼ì²âÒÇOxymapÆÊÎöÁ˱պÏÐÔÑÛ´ìÉ˺óµÄÊÓÍøÄ¤ÑªÑõ´úлÇéÐÎ £¬Ñо¿·¢Ã÷±ÕºÏÐÔÑÛ´ìÉ˺óÊÓÍøÄ¤µÄ¾²ÂöѪÑõ±¥ºÍ¶È½µµÍÒÔ¼°ÐÂÎÅÂöÑõ·Öѹ²îÔöÌí £¬ÌáÐÑ´ìÉ˺óÊÓÍøÄ¤µÄ×éÖ¯ºÄÑõÁ¿ÔöÌí¡£±ðµÄ £¬¸ÃÍŶÓʹÓôËÊÖÒÕ»¹ÆÊÎöÁËÖØ´óÐÔÑÛÍâÉ˹èÓͺã¾ÃÌî³ä¶ÔÊÓÍøÄ¤ÑªÑõ´úлµÄ¸Ä±äÇéÐÎ £¬Ñо¿·¢Ã÷¹èÓÍÌî³äÁè¼Ý9¸öÔ¿ɵ¼ÖÂÊÓÍøÄ¤µÄÐÂÎÅÂöÑõ·Öѹ²îµÄÔöÌíÒÔ¼°ÊÓÍøÄ¤¶¯ÂöÖ±¾¶±äÕ­ £¬ÎªÖØ´óÐÔÑÛÍâÉ˹èÓÍÌî³äµÄÈ¡ÓÍʱ»úÌṩÁË¿ÆÑ§ÒÀ¾Ý¡£Á½ÏîÑо¿¾ù½ÒÏþÔÚBioMed Research InternationalÔÓÖ¾¡£ÎÞ´´ÐÔµÄÊÓÍøÄ¤ÑªÑõ±¥ºÍ¶È¼ì²âΪÎÒÃǽâ¶ÁÊÓÍøÄ¤µÄѪÑõ´úл״̬ÌṩÁËÇáÓ¯¡¢ µÄ¿Í¹ÛÒÀ¾Ý £¬¶ÔÆÀ¹ÀÖÖÖÖÑÛÍâÉ˵ÄÉËÇéÒÔ¼°Ò½ÖθÉÔ¤¾ßÓÐÒ»¶¨µÄ¿ÆÑ§ÒâÒå¡£


¡¡¡¡Ê×´ÎÕ¹ÏÖ²£Á§ÌåÇгýÊõÒ½ÖÎÔöÉúÐÔÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖÐÓ¦ÓÃÇú°²ÄεµÄֹѪ»úÖÆ

¡¡¡¡Ê¹Óò£Á§ÌåÇгýÊõÒ½ÖÎÔöÉúÐÔÌÇÄò²¡ÊÓÍøÄ¤²¡±ä(PDR) £¬´¦Öóͷ£ÊÓÍøÄ¤ÐÂÉúѪ¹ÜĤʱ¾­³£Òý·¢ÊõÖгöѪ £¬µ¼ÖÂÊÖÊõʱ¼äÑÓÉì¡¢ÊÓÍøÄ¤²¡±ä´¦Öóͷ£²»³¹* £¬ÑÏÖØÓ°Ï컼ÕßÔ¤ºó¡£Çú°²ÄεÂ(triamcinolone acetonide £¬TA)ÔÚ²£Á§ÌåÇгýÊõÖи¨Öú±ê¼Ç²£Á§Ìå £¬Òѱ»ÆÕ±éÓ¦Óá£Ìì½òÒ½¿Æ´óѧ×ÜÒ½ÔºÑÛ¿ÆÑÕ»ª½ÌÊÚÑо¿ÍŶӴÓϸ½ÚÈëÊÖ £¬ÔÚ²£Á§ÌåÇгýÊõÖÐ×¢ÈëTA £¬·¢Ã÷TA¿ÅÁ£¿ÉÒÔÁýÕÖÊÓÍøÄ¤³öѪµã £¬Äܹ» ¿ØÖÆPDRÊõÖÐÊÓÍøÄ¤³öѪ¡¢ÉøÑª £¬µ«´ËÕ÷Ïóȱ·¦ÀíÂÛÒÀ¾ÝÖ§³Ö £¬Òò´Ë £¬´ÓÕ÷ÏóÈëÊÖ £¬Ñо¿²£Á§ÌåÇгýÊõÖÐTA¹ØÓÚÊÓÍøÄ¤³öѪµÄÄýѪ»úÖÆ¡£Ñо¿Ð§¹û·¢Ã÷²£Á§ÌåÇгýÊõÖв£Á§ÌåÇ»ÄÚ×¢ÈëTA¿É ¿ØÖÆPDRÊõÖÐÊÓÍøÄ¤³öѪ¡¢ÉøÑª £¬²¢ïÔÌ­ÊõºóÔٴγöѪ £¬Æä»úÖÆÓëTAÉϵ÷PAI-1 £¬¼°Ïµ÷t-PAºÍu-PAÓйØ¡£´ËÑо¿ÔÚTA¼ÈÓÐ×÷ÓõĻù´¡ÉÏ £¬½øÒ»²½ÍØ¿íÁËTAµÄÓ¦ÓùæÄ£ £¬²¢ÎªTAµÄÁÙ´²Ó¦ÓÃÌṩÀíÂÛÒÀ¾Ý¡£¸ÃÑо¿½ÒÏþÔÚ¡¶ÖлªÊµÑéÑÛ¿ÆÔÓÖ¾¡· £¬»ñµÃ¹ú¼Ò·¢Ã÷רÀû(רÀûºÅ201510351125.3) £¬²¢ÊÜÑûÔÚµÚ17½ìÅ·ÖÞ²£Á§ÌåÊÓÍøÄ¤Ñ§»á¾Û»áÉÏÐû½² £¬»ñµÃÓë»á¸÷¹úÑÛ¿ÆÍ¬Ö¾ÔÞÓþ¡£

ÔÚÏß×Éѯ
·µ»Ø
?
  • »ª±±µØÇø
  • »ªÄϵØÇø
  • Î÷ÄϵØÇø
  • »ªÖеØÇø
  • »ª¶«µØÇø
  • Î÷±±µØÇø
  • ¶«±±µØÇø
°²öÎÓéÀÖ¹ÙÍøÑÛ¿ÆÎ¢ÐŹ«ÖںŠ΢ÐŹ«ÖÚºÅ
΢²©
ÍøÕ¾µØÍ¼